APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Therapeutics Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Therapeutics Drugs Market Outlook and Growth Opportunities 2026

23 December 2025202 pages

Choose your research edition.

Industry ResearchPeptide Therapeutics Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Therapeutics Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Therapeutics Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Therapeutics Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Peptide Therapeutics Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Therapeutics Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Therapeutics Drugs market include Takeda, Teva, Sanofi, J & J, Novartis, Novo Nordisk, Merck, Eli Lilly and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peptide Therapeutics Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Therapeutics Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Therapeutics Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide Therapeutics Drugs market.

Peptide Therapeutics Drugs Segment by Company

Takeda

Teva

Sanofi

J & J

Novartis

Novo Nordisk

Merck

Eli Lilly

Ferring

AbbVie

AstraZeneca

The Medicines

Lantheus

Ipsen

CSL Vifor Group

BioMarin Pharmaceutical

Aurinia Pharmaceuticals

Apellis Pharmaceuticals

Peptide Therapeutics Drugs Segment by Type

Injection

Oral

Other

Peptide Therapeutics Drugs Segment by Application

Central Nervous System

Metabolic Disorders

Cancer

Other

Peptide Therapeutics Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Therapeutics Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide Therapeutics Drugs key companies, revenue, market share, and recent developments.

3. To split the Peptide Therapeutics Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide Therapeutics Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Therapeutics Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Therapeutics Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Therapeutics Drugs industry.

Chapter 3: Detailed analysis of Peptide Therapeutics Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide Therapeutics Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Therapeutics Drugs Industry Trends Table 2. Peptide Therapeutics Drugs Industry Drivers Table 3. Peptide Therapeutics Drugs Industry Opportunities and Challenges Table 4. Peptide Therapeutics Drugs Industry Restraints Table 5. Global Peptide Therapeutics Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Therapeutics Drugs Revenue Share by Company (2021-2026) Table 7. Global Peptide Therapeutics Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide Therapeutics Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Peptide Therapeutics Drugs Company, Product Type & Application Table 10. Global Peptide Therapeutics Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Injection Table 15. Significant Companies of Oral Table 16. Significant Companies of Other Table 17. Global Peptide Therapeutics Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Peptide Therapeutics Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Peptide Therapeutics Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Peptide Therapeutics Drugs Sales Value Share by Type (2021-2026) Table 21. Global Peptide Therapeutics Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Central Nervous System Table 23. Significant Companies of Metabolic Disorders Table 24. Significant Companies of Cancer Table 25. Significant Companies of Other Table 26. Global Peptide Therapeutics Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptide Therapeutics Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Peptide Therapeutics Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Peptide Therapeutics Drugs Sales Value Share by Application (2021-2026) Table 30. Global Peptide Therapeutics Drugs Sales Value Share by Application (2027-2032) Table 31. Global Peptide Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptide Therapeutics Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Peptide Therapeutics Drugs Sales Value Share by Region (2021-2026) Table 34. Global Peptide Therapeutics Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Peptide Therapeutics Drugs Sales Value Share by Region (2027-2032) Table 36. Global Peptide Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peptide Therapeutics Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Peptide Therapeutics Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Peptide Therapeutics Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Peptide Therapeutics Drugs Sales Value Market Share by Country (2027-2032) Table 41. Takeda Company Information Table 42. Takeda Business Overview Table 43. Takeda Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Peptide Therapeutics Drugs Product Portfolio Table 45. Takeda Recent Development Table 46. Teva Company Information Table 47. Teva Business Overview Table 48. Teva Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Peptide Therapeutics Drugs Product Portfolio Table 50. Teva Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Peptide Therapeutics Drugs Product Portfolio Table 55. Sanofi Recent Development Table 56. J & J Company Information Table 57. J & J Business Overview Table 58. J & J Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. J & J Peptide Therapeutics Drugs Product Portfolio Table 60. J & J Recent Development Table 61. Novartis Company Information Table 62. Novartis Business Overview Table 63. Novartis Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novartis Peptide Therapeutics Drugs Product Portfolio Table 65. Novartis Recent Development Table 66. Novo Nordisk Company Information Table 67. Novo Nordisk Business Overview Table 68. Novo Nordisk Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novo Nordisk Peptide Therapeutics Drugs Product Portfolio Table 70. Novo Nordisk Recent Development Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Merck Peptide Therapeutics Drugs Product Portfolio Table 75. Merck Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eli Lilly Peptide Therapeutics Drugs Product Portfolio Table 80. Eli Lilly Recent Development Table 81. Ferring Company Information Table 82. Ferring Business Overview Table 83. Ferring Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ferring Peptide Therapeutics Drugs Product Portfolio Table 85. Ferring Recent Development Table 86. AbbVie Company Information Table 87. AbbVie Business Overview Table 88. AbbVie Peptide Therapeutics Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AbbVie Peptide Therapeutics Drugs Product Portfolio Table 90. AbbVie Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Peptide Therapeutics Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. The Medicines Company Information Table 97. The Medicines Business Overview Table 98. The Medicines Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. The Medicines Peptide Therapeutics Drugs Product Portfolio Table 100. The Medicines Recent Development Table 101. Lantheus Company Information Table 102. Lantheus Business Overview Table 103. Lantheus Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Lantheus Peptide Therapeutics Drugs Product Portfolio Table 105. Lantheus Recent Development Table 106. Ipsen Company Information Table 107. Ipsen Business Overview Table 108. Ipsen Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Ipsen Peptide Therapeutics Drugs Product Portfolio Table 110. Ipsen Recent Development Table 111. CSL Vifor Group Company Information Table 112. CSL Vifor Group Business Overview Table 113. CSL Vifor Group Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. CSL Vifor Group Peptide Therapeutics Drugs Product Portfolio Table 115. CSL Vifor Group Recent Development Table 116. BioMarin Pharmaceutical Company Information Table 117. BioMarin Pharmaceutical Business Overview Table 118. BioMarin Pharmaceutical Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. BioMarin Pharmaceutical Peptide Therapeutics Drugs Product Portfolio Table 120. BioMarin Pharmaceutical Recent Development Table 121. Aurinia Pharmaceuticals Company Information Table 122. Aurinia Pharmaceuticals Business Overview Table 123. Aurinia Pharmaceuticals Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Aurinia Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio Table 125. Aurinia Pharmaceuticals Recent Development Table 126. Apellis Pharmaceuticals Company Information Table 127. Apellis Pharmaceuticals Business Overview Table 128. Apellis Pharmaceuticals Peptide Therapeutics Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Apellis Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio Table 130. Apellis Pharmaceuticals Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Peptide Therapeutics Drugs Product Image Figure 2. Global Peptide Therapeutics Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Therapeutics Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Therapeutics Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Injection Image Figure 8. Oral Image Figure 9. Other Image Figure 10. Global Peptide Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Peptide Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Peptide Therapeutics Drugs Sales Value Share by Type (2021-2032) Figure 13. Central Nervous System Image Figure 14. Metabolic Disorders Image Figure 15. Cancer Image Figure 16. Other Image Figure 17. Global Peptide Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peptide Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Peptide Therapeutics Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Peptide Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Peptide Therapeutics Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Peptide Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Peptide Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Peptide Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Peptide Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Peptide Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Peptide Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Peptide Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Peptide Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Peptide Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Peptide Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Central Nervous System
  • Metabolic Disorders
  • Cancer
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • J & J
  • Novartis
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Ferring
  • AbbVie
  • AstraZeneca
  • The Medicines
  • Lantheus
  • Ipsen
  • CSL Vifor Group
  • BioMarin Pharmaceutical
  • Aurinia Pharmaceuticals
  • Apellis Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Therapeutics Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Therapeutics Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide Therapeutics Drugs Market Dynamics
  1. 2.1 Peptide Therapeutics Drugs Industry Trends
  2. 2.2 Peptide Therapeutics Drugs Industry Drivers
  3. 2.3 Peptide Therapeutics Drugs Industry Opportunities and Challenges
  4. 2.4 Peptide Therapeutics Drugs Industry Restraints
3 Peptide Therapeutics Drugs Market by Company
  1. 3.1 Global Peptide Therapeutics Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Therapeutics Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Therapeutics Drugs Company Ranking (2024-2026)
  4. 3.4 Global Peptide Therapeutics Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide Therapeutics Drugs Company Product Type and Application
  6. 3.6 Global Peptide Therapeutics Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide Therapeutics Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide Therapeutics Drugs Market by Type
  1. 4.1 Peptide Therapeutics Drugs Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.1.3 Other
  5. 4.2 Global Peptide Therapeutics Drugs Sales Value by Type
  6. 4.2.1 Global Peptide Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Therapeutics Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Peptide Therapeutics Drugs Sales Value Share by Type (2021-2032)
5 Peptide Therapeutics Drugs Market by Application
  1. 5.1 Peptide Therapeutics Drugs Application Introduction
  2. 5.1.1 Central Nervous System
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Cancer
  5. 5.1.4 Other
  6. 5.2 Global Peptide Therapeutics Drugs Sales Value by Application
  7. 5.2.1 Global Peptide Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Peptide Therapeutics Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Peptide Therapeutics Drugs Sales Value Share by Application (2021-2032)
6 Peptide Therapeutics Drugs Regional Value Analysis
  1. 6.1 Global Peptide Therapeutics Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Therapeutics Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide Therapeutics Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide Therapeutics Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Therapeutics Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Peptide Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide Therapeutics Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide Therapeutics Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide Therapeutics Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Peptide Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide Therapeutics Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
7 Peptide Therapeutics Drugs Country-level Value Analysis
  1. 7.1 Global Peptide Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Therapeutics Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide Therapeutics Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide Therapeutics Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Peptide Therapeutics Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Peptide Therapeutics Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Peptide Therapeutics Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 J & J
  20. 8.4.1 J & J Company Information
  21. 8.4.2 J & J Business Overview
  22. 8.4.3 J & J Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 J & J Peptide Therapeutics Drugs Product Portfolio
  24. 8.4.5 J & J Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Peptide Therapeutics Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Peptide Therapeutics Drugs Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Peptide Therapeutics Drugs Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Peptide Therapeutics Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Ferring
  50. 8.9.1 Ferring Company Information
  51. 8.9.2 Ferring Business Overview
  52. 8.9.3 Ferring Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ferring Peptide Therapeutics Drugs Product Portfolio
  54. 8.9.5 Ferring Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Peptide Therapeutics Drugs Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Peptide Therapeutics Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 The Medicines
  68. 8.12.1 The Medicines Company Information
  69. 8.12.2 The Medicines Business Overview
  70. 8.12.3 The Medicines Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 The Medicines Peptide Therapeutics Drugs Product Portfolio
  72. 8.12.5 The Medicines Recent Developments
  73. 8.13 Lantheus
  74. 8.13.1 Lantheus Company Information
  75. 8.13.2 Lantheus Business Overview
  76. 8.13.3 Lantheus Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lantheus Peptide Therapeutics Drugs Product Portfolio
  78. 8.13.5 Lantheus Recent Developments
  79. 8.14 Ipsen
  80. 8.14.1 Ipsen Company Information
  81. 8.14.2 Ipsen Business Overview
  82. 8.14.3 Ipsen Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ipsen Peptide Therapeutics Drugs Product Portfolio
  84. 8.14.5 Ipsen Recent Developments
  85. 8.15 CSL Vifor Group
  86. 8.15.1 CSL Vifor Group Company Information
  87. 8.15.2 CSL Vifor Group Business Overview
  88. 8.15.3 CSL Vifor Group Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CSL Vifor Group Peptide Therapeutics Drugs Product Portfolio
  90. 8.15.5 CSL Vifor Group Recent Developments
  91. 8.16 BioMarin Pharmaceutical
  92. 8.16.1 BioMarin Pharmaceutical Company Information
  93. 8.16.2 BioMarin Pharmaceutical Business Overview
  94. 8.16.3 BioMarin Pharmaceutical Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BioMarin Pharmaceutical Peptide Therapeutics Drugs Product Portfolio
  96. 8.16.5 BioMarin Pharmaceutical Recent Developments
  97. 8.17 Aurinia Pharmaceuticals
  98. 8.17.1 Aurinia Pharmaceuticals Company Information
  99. 8.17.2 Aurinia Pharmaceuticals Business Overview
  100. 8.17.3 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
  102. 8.17.5 Aurinia Pharmaceuticals Recent Developments
  103. 8.18 Apellis Pharmaceuticals
  104. 8.18.1 Apellis Pharmaceuticals Company Information
  105. 8.18.2 Apellis Pharmaceuticals Business Overview
  106. 8.18.3 Apellis Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Apellis Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
  108. 8.18.5 Apellis Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst